Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives.
Alzheimer's disease (AD) is by far the most common form of dementia in the elderly and concerns one out of three individuals over 85. Like other neurodegenerative disorders such as Parkinson, Hungtington or prion diseases, AD is characterized by the formation of amyloid plaques in the central nervous system. In the brain of AD patients, the main component of these abnormal deposits is an aggregated form of the so-called amyloid beta-peptide (Abeta), which is produced from a large trans-membrane type-1 protein, the beta-amyloid precursor protein (betaAPP), by the sequential action of the beta- and gamma-secretases. Beside these two amyloidogenic proteolytic attacks, betaAPP is targeted by a third enzyme termed alpha-secretase. Of utmost importance, this cleavage, which can be of constitutive or regulated origin, occurs right in the middle of the Abeta sequence, thus precluding its production. For this reason, and because the sAPPalpha secreted fragment derived from this cleavage displays beneficial effects, tremendous efforts have been made recently in order to both identify the proteases involved and the way they are regulated. More recently, it emerged that alpha-secretase was also responsible for the physiological processing of the cellular prion protein (PrP(c)) in the middle of its toxic 106-126 sequence. This review will focus on the recent advances in the alpha-secretase pathways regulation and will discuss the putative therapeutic approaches that could be envisioned concerning the treatment of two apparently distinct diseases that share common denominators according to their metabolism.
Vincent
Bruno
B
Institut de Pharmacologie Moléculaire et Cellulaire, UMR 6097 CNRS/Université de Nice-Sophia-Antipolis, Equipe labellisée Fondation pour la Recherche Médicale, 660 route des Lucioles, 06560 Valbonne, France. vincentb@ipmc.cnrs.fr
Cisse
Moustapha Alfa
MA
Sunyach
Claire
C
Guillot-Sestier
Marie-Victoire
MV
Checler
Frédéric
F
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D000818:Animals; D006801:Humans; D018621:PrPC Proteins / Q000378:metabolism*; D017096:Prion Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism
D016564:Amyloid beta-Protein Precursor; D018621:PrPC Proteins; D053829:Amyloid Precursor Protein Secretases